In patients with essential hypertension who have apparently normal renal function it is not unusual for the serum uric acid to be elevated.
Gout is a consequence of hyperuricaemia, although the serum uric acid may not be elevated during an acute attack of gout, or on incidental blood sampling.
The prevalence of asymptomatic hyperuricaemia is high amongst Polynesian women. This may be due to a genetic predisposition to hyperuricaemia amongst Polynesians reflected in their reduced fractional clearance of uric acid compared with their UK counterparts. However, hypertension does not contribute to this reduced clearance and is thus not a part of the same (presumed genetic) predisposition to gout. 4 Hypertension may nevertheless be associated with hyperuricaemia for a number of reasons. To better understand these it is instructive to review briefly the mechanisms of hyperuricaemia.
Uric acid is a breakdown product of purine metabolism. It is produced in the liver and excreted largely through the kidneys. Uric acid is completely filtered at the glomerulus, almost fully resorbed at the proximal convoluted tubule and actively secreted further along the tubule. 5 Hyperuricaemia occurs as a result of either overproduction or underexcretion of uric acid or both. 6 Overproduction of uric acid occurs with rare genetic disorders, alcohol consumption 7 and high purine intake. Tissue breakdown particularly in the treatment of haematological malignancies releases purines. Some alcoholic beverages (notably beer) contain considerable quantities of purines and thus contribute to uric acid overproduction. treated with diuretics. This is significant clinically; diuretic treatment of hypertension is associated with an increased risk of hyperuricaemia. 2 Impairment of renal function may cause hyperuricaemia through reduction in both filtration and secretion of uric acid.
Essential hypertension enhances proximal tubular reabsorption 9 and depresses renal tubular secretion of uric acid. 10 Indeed raised urate levels have been used as an indicator of renal impairment due to hypertension; 11 20-40% of patients with essential hypertension are hyperuricaemic. 3 Alcohol consumption above a threshold of 2 or 3 units daily is associated with an increase in blood pressure. 12 Hyperuricaemia also occurs with diabetes mellitus 13 and eclampsia. 14 Hypertension is one of the defining 14 features of the latter condition and is associated with the former.
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Significance of asymptomatic hyperuricaemia in hypertension
Is the presence of hyperuricaemia clinically important in a hypertensive patient? The answer depends upon the causative factors and the degree of hyperuricaemia; the risk of future attacks of gout increases with the serum uric acid concentration. 15 The overall incidence of gout is three times higher in hypertensive patients than in normotensive patients. 15 Some of this increased incidence is probably due to diuretic treatment. 2 In people who have never had symptoms related to hyperuricaemia there is no virtue in treating the condition. 16 Nevertheless many physicians are unhappy to leave very high levels of serum uric acid untreated even in asymptomatic patients; certainly once tophaceous gout has developed, treatment with urate-lowering drugs is advised. 16 Hyperuricaemia also predisposes to nephrolithiasis. 15 Most importantly, the discovery of hyperuricaemia in a hypertensive patient may lead to identification of correctible risk factors for cardiovascular disease in the patient's lifestyle. Hyperlipidaemia frequently coexists with hyperuricaemia; 2 the patient (usually male) may be able to correct his hyperlipidaemia by modification of his diet and by reduction in his alcohol consumption. Hypertension in heavy drinkers will improve with a reduction in alcohol consumption.
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Treatment of asymptomatic hyperuricaemia in hypertensive patients
Since the risk of gout relates to the serum uric acid concentration 15 patients with mild hyperuricaemia (serum uric acid level below 410 mol/L and a 0.1% annual incidence of gouty arthritis) need no drug intervention. However, patients with serum uric acid levels above 530 mol/L have a 4.9% annual incidence of gout;
15 patients with such uric acid levels should be warned of this risk. Many will elect to try dietary measures or to wait for gout to develop before starting urate-lowering drug therapy.
Nevertheless attempts should be made to control mild-to-moderate hyperuricaemia (serum urate 410 to 530 mol/L). The patient's drug regime should be scrutinised. If the treatment of the patient's hypertension includes a thiazide diuretic the potential benefits and risks of other hypotensive agents 17 should be weighed against the risk of future attacks of gout. A patient with a heavy alcohol or food intake may prefer abstemiousness to taking uric acid-lowering drugs.
If urate-lowering drugs are required, the first choice is allopurinol because of its relatively benign adverse reaction profile. 16 Allopurinol needs to be taken daily for an indefinite period to maintain its full effect. 18 Patients who are intolerant of allopurinol are usually offered uricosuric drugs. These drugs may, however, cause crystallisation of uric acid in the urine. 19 In conclusion, patients taking diuretic drugs for hypertension should have their serum uric acid levels measured approximately every year. If rising levels of serum uric acid are discovered, use of alternative hypotensive medication should be considered. If relevant, attempts should be made to reduce uric acid levels without medications by dietary manipulation and by reduction of alcohol consumption. If these measures are not successful, treatment with a uric acid-lowering drug should be considered for the patient with very high serum uric acid levels (530 mol/L or above).
